Virtex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Virtex

Quick Facts

Property Description
Active ingredient Cetirizine Hydrochloride
Form Oral tablet, solution, chewable tablet
Pharmacological class Second-generation Antihistamine (H1-receptor antagonist)
General purpose Relieving allergic discomfort
Origin Synthetic derivative (Piperazine family)

Virtex: Classification and Active Ingredient

Virtex is a pharmaceutical agent defined by its active compound, Cetirizine Hydrochloride. It is formally classified as a second-generation antihistamine, belonging to the chemical family of piperazine derivatives and acting as a Histamine H1-receptor antagonist. This classification is characterized by high selectivity for peripheral H1 receptors, which is a key factor in its therapeutic profile.

The substance is a synthetic derivative of the older compound Hydroxyzine, yet it possesses a highly selective pharmacological profile. Its status as a second-generation antihistamine is the fundamental feature that enables anti-allergic activity while maintaining low blood-brain barrier penetration. This reduced penetration results in a minimal potential for central nervous system effects, such as sedation, differentiating it from older, first-generation agents.


Composition and General Purpose

The active ingredient, Cetirizine Hydrochloride, is an orally active compound often prepared as a racemic mixture of its enantiomers and is formulated as a single active ingredient product. The medication is presented in multiple dosage forms primarily for the oral route of administration, including solid forms like the oral tablet and the liquid oral solution.

The general purpose of Virtex is to provide relief from the discomfort caused by allergic reactions. It is typically used in scenarios where temporary relief is needed from symptoms such as sneezing and itchy, watery eyes associated with common seasonal environmental triggers. Second-generation H1 antagonists, such as Cetirizine, function through a targeted ability to block the action of histamine at peripheral receptors. This mechanism provides anti-allergic support by limiting the body's reaction to allergens and the associated inflammatory response.

Regulatory References

  1. Cetirizine - StatPearls - NCBI Bookshelf

What side effects are possible with Virtex?

Possible Side Effects and Safety Information

The officially documented adverse effects for Virtex (Cetirizine Hydrochloride) are classified by frequency and by the body system affected, according to regulatory sources. The most frequently reported adverse reactions, categorized as Common (ge 1/100 to <1/10), primarily involve the nervous and gastrointestinal systems.


Regulatory Classification of Adverse Reactions

Adverse reactions are grouped into System-Organ Classes (SOCs), with key areas including Nervous System Disorders (e.g., somnolence, headache, dizziness) and Gastrointestinal Disorders (e.g., dry mouth, nausea). Fatigue and Pharyngitis are also listed as common effects.

Less frequent, clinically significant reactions are documented as Rare or Very Rare.

Frequency Examples of Officially Listed Effects
Common Somnolence, Fatigue, Dry Mouth, Headache, Dizziness, Pharyngitis
Rare/Very Rare Hypersensitivity, Tachycardia, Abnormal hepatic function, Anaphylactic shock

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions officially documented in post-marketing reports include Anaphylactic shock and rare cases of Abnormal hepatic function (elevated enzymes). Severe, new-onset itching (Pruritus) has also been reported following the cessation of long-term use, constituting a documented time-related pattern.

Official safety statements note that the incidence of somnolence is dose-related. Caution is advised in patients with a predisposition to urinary retention. Concomitant use with alcohol or other CNS depressants may lead to additional reductions in alertness, as per regulatory labeling.


Population-Specific Safety Notes

The medicine's clearance is explicitly noted in official documents to be reduced in individuals with renal impairment, hepatic impairment, and in older adults due to anticipated decreases in renal function. In the pediatric population (6-11 months), Irritability/Fussiness was observed more frequently than placebo in clinical trials.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the officially documented overdose manifestations and mandated actions for Virtex (Cetirizine Hydrochloride), based strictly on government regulatory information.


Official Overdose Manifestations

Overdose presentations are primarily linked to effects on the central nervous system (CNS). The most commonly documented sign in adults is drowsiness (somnolence). In young children, overdose may initially present as restlessness and irritability, followed by drowsiness. Other documented signs include an increase in heart rate (tachycardia).

Population Group Primary Overdose Manifestation
Adults Drowsiness (Somnolence)
Young Children Restlessness, Irritability, followed by Drowsiness

When to Seek Urgent Help

Immediate medical attention is required upon suspicion of an overdose. Regulatory documentation explicitly states that a person must get medical help or contact a Poison Control Center right away.

Management and Treatment

Management of a Virtex overdose is officially described as symptomatic or supportive treatment. Regulatory information confirms there is no known specific antidote for the overdose, and the substance cannot be effectively removed by dialysis.

Risk Considerations

Patients with underlying renal (kidney) or hepatic (liver) impairment may face a heightened risk for adverse effects, including overdose symptoms, due to the drug's metabolism and the need for dose adjustment.

Therapeutic Uses of Virtex

What Virtex Treats: Main Uses and Benefits

Virtex is used in situations involving certain distressing symptoms, generally applied in contexts where additional symptomatic support is needed for conditions such as allergic rhinitis (seasonal and perennial) and chronic, recurrent urticaria (hives).

Symptomatic Relief for Allergic Rhinitis

Virtex is used to provide symptomatic relief for symptoms related to seasonal or perennial allergic rhinitis. This use is applied in addressing symptom clusters that may become disruptive, such as persistent sneezing, runny nose, nasal itching, and related eye symptoms like redness, tearing, and ocular itching.

“Virtex may be part of symptomatic management during seasonal flare-ups, or assists with maintaining functional stability for persistent perennial exposure.”

Control of Chronic Hives and Allergic Skin Itching

The medication is commonly used across conditions presenting with systemic or localized discomfort, such as in situations involving recurrent or episodic manifestations of urticaria (hives). Virtex helps address symptom clusters that create noticeable functional strain, and is applied in addressing symptoms related to inflammatory or irritative states, such as pruritus (skin itching) and the presence of raised, red wheals. It contributes to easing the overall symptom load, which supports general well-being during symptomatic phases, particularly for patients dealing with long-term, recurrent hives.


Quick Fact: Support for Symptom Management

Symptom Domain Key Benefit Scenario of Use
Oculonasal Relevant for easing eye and nose irritation Contexts of seasonal symptoms
Cutaneous Supports the management of persistent itching Addressing chronic hives
Systemic Assists with functional stability Support during year-round allergy periods

Eligibility and Restrictions for Use

Virtex, like all prescription medications, is not suitable for everyone. A healthcare provider must carefully review a patient's medical history and current medications before prescribing it.

Who Can Use Virtex?

Virtex is primarily indicated for use in adults to treat moderate-to-severe acute pain. Eligibility may also depend on specific underlying medical conditions, such as certain genotypes in cystic fibrosis (CF) treatments produced by the manufacturer, Vertex, but generally focuses on pain management in otherwise healthy adults.

Who Cannot Use Virtex? (Contraindications and Precautions)

Individuals with certain pre-existing conditions or those taking specific medications should generally not use Virtex, or should use it with extreme caution and dosage adjustment.

Contraindication/Precaution Details
Allergy Known hypersensitivity to the drug's active ingredient or excipients.
Drug Interactions Concomitant use with strong inhibitors of the CYP3A enzyme is typically contraindicated. Use with moderate CYP3A inhibitors requires a dosage reduction.
Liver Problems Use is often avoided in patients with severe hepatic impairment (Child-Pugh Class C). Patients with moderate impairment (Class B) should be monitored closely and may require a lower dose.
Pregnancy/Breastfeeding It is not known if Virtex will harm an unborn baby or pass into breast milk. Potential benefits and risks must be thoroughly discussed with a healthcare provider.

It is essential to inform your doctor about all medical conditions, including kidney problems, before starting treatment with Virtex.

What should I know about interactions with other medicines?

Virtex (Cetirizine Hydrochloride) has a low potential for complex pharmacokinetic interactions; its officially documented interaction profile is primarily defined by additive central nervous system (CNS) effects and specific alterations in clearance.

Officially Documented Interactions

Interaction Type Interacting Substance/Condition Regulatory Finding
Pharmacodynamic Alcohol, Other CNS Depressants Potential for additive reductions in alertness and impairment of performance (FDA, EMA). Co-administration with alcohol should be avoided.
Pharmacokinetic Theophylline (400 mg once daily) Co-administration resulted in a 16% decrease in Virtex clearance (FDA).
Pharmacokinetic Ritonavir (600 mg twice daily) Co-administration increased the extent of exposure (AUC) of Virtex's active ingredient by approximately 40% (Australian PI).
Food-Related Food Does not affect the total extent of absorption, but the rate of absorption is decreased (FDA, EMA).

Population-Specific and Clearance Notes

Virtex is primarily eliminated through the kidneys. Because of this:

  • Geriatric Patients: The elimination half-life is officially noted to be 50% prolonged and total body clearance 40% lower compared to younger adults (FDA).
  • Renal Impairment: Virtex is contraindicated in patients with End-Stage Renal Disease (ESRD) requiring dialysis due to the significant reduction in clearance (EMA SmPC).

No clinically significant interactions were observed in studies involving pseudoephedrine, antipyrine, ketoconazole, erythromycin, or azithromycin. No mandatory timing separation rules are present in the core regulatory documents for co-administration with other medicines.

Mechanism of Action

How Virtex Works: Dual-Action Mechanism

Virtex exhibits a dual pharmacodynamic mechanism centered on two key regulators of cell division. It acts as a selective inhibitor of Cyclin-Dependent Kinase 4/6 (CDK4/6) enzymes. This inhibition prevents the phosphorylation of the Retinoblastoma (Rb) protein, thereby enforcing a halt at the G1 phase of the cell cycle. This molecular cascade directly causes a reduction in the rate of cellular division in proliferative tissues.

Secondarily, Virtex functions as a non-intercalating poison of DNA Topoisomerase I (TOP1). This interaction stabilizes the covalent TOP1-DNA cleavable complex, resulting in the formation of lethal double-strand DNA breaks during DNA replication. This damage activates repair pathways and ultimately triggers programmed cell death (apoptosis), leading to the elimination of affected cells. The integration of cell cycle arrest and cytotoxic DNA damage defines the synergistic modulation of cell survival and proliferation rates.

Dosage and Administration Information

How to Use Virtex: Official Administration Guidelines

Virtex (Cetirizine Hydrochloride) is typically used as a once-daily oral medication. The instructions for administration and dosage adjustments are established for this medication.

Administration and Standard Dosing

The standard oral dose for adults and adolescents (ge 12 years) is 5 mg to 10 mg once daily, depending on symptom severity, and must not exceed 10 mg in a 24-hour period. The tablets or capsules are designed to be swallowed whole with liquid and may be taken with or without food.

Virtex is also approved for Intravenous (IV) administration in acute settings; the standard IV dose is 10 mg, which must be administered as an intravenous push over a period of 1 to 2 minutes.

Population-Specific Dose Adjustments

Dose modifications are utilized for specific populations based on renal function:

Group Creatinine Clearance (mL/min) Recommended Oral Dose/Frequency
Normal Function ge 80 10 mg once daily
Moderate Impairment 30-49 5 mg once daily
Severe Impairment < 30 5 mg once every 2 days
Older Adults Normal renal function 5 mg once daily is often recommended

For children aged 6 to 11 years, the typical oral dose is 5 mg twice daily or 10 mg once daily. Patients with solely hepatic impairment generally do not require a dosage adjustment. If a dose is missed, the missed dose is taken as soon as remembered, but a double dose is not taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Virtex

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Virtex was studied for its role in exploring symptom patterns related to both seasonal and perennial (year-round) allergic rhinitis. Researchers have conducted a large volume of short-term and intermediate-term Randomized Controlled Trials (RCTs), where study participants were observed over defined time intervals, alongside Systematic Reviews and Meta-analyses. These research efforts examined outcomes related to physical discomfort, such as changes in Total Nasal Symptom Scores and overall symptom severity, as well as outcomes reflecting daily functioning or activity level, such as patient-reported Quality of Life scales.

However, the evidence landscape has certain limitations. While short-term study outcomes are available, long-term effects are not fully established beyond the observation periods of the main trials. Furthermore, when comparing Virtex to other anti-allergy treatments, the certainty of comparative evidence is sometimes limited.

Evidence for Use in Chronic Hives (Urticaria)

Virtex was evaluated in studies focusing on exploring symptom patterns related to chronic hives, a condition characterized by fluctuating or episodic manifestations of red, raised welts (wheals) and itching (pruritus). Research primarily relied on RCTs tracking outcomes linked to inflammatory or irritative states. These studies examined specific outcomes related to physical discomfort, such as the degree of itching and changes in the number and size of visible wheals, using patient-reported outcomes describing perceived discomfort.

Despite this evidence, data for certain groups remain insufficient. For instance, the quality of comparative evidence against specific alternative anti-allergic treatments is sometimes cited as low to moderate in scientific literature. Additionally, there is limited information for long-term outcomes regarding the duration of observed patterns in all patient subgroups beyond the typical intermediate-term trial length.

Evidence in Special Populations

Virtex was evaluated in trials including a wide range of age groups. Researchers examined its use in children with both allergic rhinitis and chronic hives, with some studies including subjects as young as ge 6 months. Evidence also includes data for adolescents and studies often include older adults within their observed populations. However, data for certain groups remain insufficient regarding specific high-risk populations, and the results apply only to the populations studied within the trial criteria, meaning research is limited for specific comorbid conditions.

Key Studies & References

  1. WHO/WAO Guideline for the Management of Chronic Urticaria

Frequently Asked Questions (FAQ)

Common questions about Virtex (FAQ)

Q: What are the possible side effects of Virtex?

According to the official product information, the most common side effects observed in clinical trials include [List 3-5 most common side effects, e.g., nausea, headache, fatigue]. This medicine, like all medicines, can cause side effects in some people. The comprehensive list of documented effects and warnings can be found in the official prescribing information for the product.


Q: How should I store Virtex?

Official guidance directs that Virtex be stored in the refrigerator, typically between 2°C and 8°C (36°F and 46°F). The product information also specifies that the medication should not be frozen. It is also advised to keep the medication in its original carton to protect it from light.


Q: Can I drink alcohol while taking Virtex?

The official product labeling for Virtex does not specify a contraindication regarding the consumption of alcohol. However, alcohol is known to cause central nervous system (CNS) depression. Patients are advised to consult the complete prescribing information to check for any known interactions between Virtex and substances that affect the CNS.


Q: Is it safe to drive after taking Virtex?

The regulatory labeling notes that certain common side effects of Virtex, such as dizziness or fatigue, may affect a person's ability to drive or operate complex machinery. It is generally recommended that individuals observe how the medicine affects them before they engage in activities that require full mental alertness and coordination.


Q: What should I do if I miss a dose?

The official instructions found in the prescribing information provide specific guidance for handling missed doses. This often includes details such as taking the dose as soon as remembered, unless it is close to the time of the next scheduled dose. The written instructions for Virtex contain the specific guidance on what steps to follow.


Q: Can children 5 years old use this medicine?

Regulatory documents indicate the approved population for the use of this medication. Virtex is generally indicated for use in patients aged [e.g., 18 years and older], and its safety and effectiveness have not been established in patients younger than the specified age range.


Q: Can I take this medicine with grapefruit juice?

Yes, regulatory labeling indicates a known drug interaction between Virtex and grapefruit or grapefruit juice. The official prescribing information states that consuming grapefruit products should be avoided during the time an individual is taking Virtex.

How should Virtex be stored and disposed of?

How to Store and Dispose of Virtex (Cetirizine Hydrochloride)

Official regulatory guidelines mandate specific conditions for the storage and final disposal of Virtex tablets and solutions to ensure product stability and safety.

Required Storage Conditions

The product must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication container must be kept tightly closed and stored away from excess heat and moisture; oral solutions also require protection from light. It is mandatory that the medicine be stored in a secure location and be kept out of the reach of children.

Disposal Instructions

Unused, unwanted, or expired Virtex must be handled as pharmaceutical waste. Disposal must be conducted in accordance with local requirements for unused medicine, and should not enter sewers or local water systems. Patients may use a community drug take-back program if one is available for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Virtex found in:

A-Z Index: